Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
10.1097/CM9.0000000000002629
- Author:
Baojun SUO
1
;
Xueli TIAN
2
;
Hua ZHANG
3
;
Haoping LU
1
;
Cailing LI
1
;
Yuxin ZHANG
1
;
Xinlu REN
1
;
Xingyu YAO
1
;
Liya ZHOU
1
;
Zhiqiang SONG
1
Author Information
1. Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China.
2. Digestive Disease Research Center of Peking University, Beijing 100191, China.
3. Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Bismuth/therapeutic use*;
Metronidazole/therapeutic use*;
Esomeprazole/pharmacology*;
Minocycline/pharmacology*;
Helicobacter pylori;
Potassium Citrate/therapeutic use*;
Anti-Bacterial Agents;
Tetracycline/adverse effects*;
Helicobacter Infections/drug therapy*;
Drug Therapy, Combination;
Amoxicillin
- From:
Chinese Medical Journal
2023;136(8):933-940
- CountryChina
- Language:English
-
Abstract:
BACKGROUND:Given the general unavailability, common adverse effects, and complicated administration of tetracycline, the clinical application of classic bismuth quadruple therapy (BQT) is greatly limited. Whether minocycline can replace tetracycline for Helicobacter pylori ( H . pylori ) eradication is unknown. We aimed to compare the eradication rate, safety, and compliance between minocycline- and tetracycline-containing BQT as first-line regimens.
METHODS:This randomized controlled trial was conducted on 434 naïve patients with H . pylori infection. The participants were randomly assigned to 14-day minocycline-containing BQT group (bismuth potassium citrate 110 mg q.i.d., esomeprazole 20 mg b.i.d., metronidazole 400 mg q.i.d., and minocycline 100 mg b.i.d.) and tetracycline-containing BQT group (bismuth potassium citrate/esomeprazole/metronidazole with doses same as above and tetracycline 500 mg q.i.d.). Safety and compliance were assessed within 3 days after eradication. Urea breath test was performed at 4-8 weeks after eradication to evaluate outcome. We used a noninferiority test to compare the eradication rates of the two groups. The intergroup differences were evaluated using Pearson chi-squared or Fisher's exact test for categorical variables and Student's t -test for continuous variables.
RESULTS:As for the eradication rates of minocycline- and tetracycline-containing BQT, the results of both intention-to-treat (ITT) and per-protocol (PP) analyses showed that the difference rate of lower limit of 95% confidence interval (CI) was >-10.0% (ITT analysis: 181/217 [83.4%] vs . 180/217 [82.9%], with a rate difference of 0.5% [-6.9% to 7.9%]; PP analysis: 177/193 [91.7%] vs . 176/191 [92.1%], with a rate difference of -0.4% [-5.6% to 6.4%]). Except for dizziness more common (35/215 [16.3%] vs . 13/214 [6.1%], P = 0.001) in minocycline-containing therapy groups, the incidences of adverse events (75/215 [34.9%] vs . 88/214 [41.1%]) and compliance (195/215 [90.7%] vs . 192/214 [89.7%]) were similar between the two groups.
CONCLUSION:The eradication efficacy of minocycline-containing BQT was noninferior to tetracycline-containing BQT as first-line regimen for H . pylori eradication with similar safety and compliance.
TRIAL REGISTRATION:ClinicalTrials.gov, ChiCTR 1900023646.
